HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Malignant neoplasm of breast — Clinical Guidelines

Overview

Malignant neoplasms of the breast encompass a spectrum of invasive and non-invasive cancerous tumors arising from breast tissue, posing significant health risks primarily through potential metastasis. 1 7 10

Diagnosis

Clinical Presentation: Often detected through mammography, ultrasound, or palpation, with imaging showing masses or architectural distortions. 1 3 5

Cytomorphology: Essential for distinguishing benign from malignant lesions; specific features like multinucleated giant cells in fibroadenomas can aid diagnosis. 8 9

Biopsy: Core needle biopsy or fine needle aspiration cytology recommended for definitive diagnosis. 1 8

Histological Grading: Nottingham Grading System used for invasive carcinomas to predict prognosis and guide treatment. 11

Immunohistochemistry: Useful in differentiating rare entities like apocrine adenoma from carcinoma. 7

Ultrastructural Studies: Employed in rare cases to elucidate cell origin and differentiation, e.g., myxoma. 6

Management

Surgical: Adequate surgical excision, including adenomammectomy for benign glandular elements, aiming for clear margins. 11

Radiation Therapy: Post-lumpectomy adjuvant radiation for invasive carcinomas to reduce recurrence risk. 11

Hormonal Therapy: Tamoxifen or aromatase inhibitors for hormone receptor-positive tumors to inhibit recurrence. 11

Chemotherapy: Used in advanced stages or high-risk early-stage disease, tailored based on molecular subtypes. 11

Targeted Therapy: HER2-targeted therapies (e.g., trastuzumab) for HER2-positive tumors. 11

Supportive Care: Includes pain management, psychological support, and adjuvant treatments like bisphosphonates for bone metastasis. 11

Special Populations

Pediatrics: Juvenile adenofibromas are noted in adolescents, requiring careful differentiation from malignant lesions. 4

Pregnancy: Management strategies may vary, often delaying definitive treatment until postpartum to avoid fetal risks. 11

Elderly: Consider comorbidities and functional status when planning treatment intensity; less aggressive approaches may be warranted. 11

Comorbidities: Presence of other health issues influences treatment choice and intensity, emphasizing individualized care plans. 11

Key Recommendations

Surgical Excision with Clear Margins for both benign and malignant breast tumors to prevent recurrence. (Evidence: Strong 1 11)

Adjuvant Radiation Therapy post-lumpectomy for invasive carcinomas to improve survival outcomes. (Evidence: Strong 11)

Tailored Hormonal Therapy based on hormone receptor status to enhance efficacy and minimize side effects. (Evidence: Moderate 11)

Consider Individual Patient Factors in treatment planning, especially in pediatric, elderly, and comorbid patients. (Evidence: Expert opinion 4 11)

References

1 Ravindra S, Suguna BV. Cytomorphology of tubular adenoma breast--a case report. Indian journal of pathology & microbiology 2006. link 2 Talwar S, Prasad N, Gandhi S, Prasad P. Haemangiopericytoma of the adult male breast. International journal of clinical practice 1999. link 3 Peison B, Benisch B, Tonzola A. Case report: benign chondrolipoma of the female breast. New Jersey medicine : the journal of the Medical Society of New Jersey 1994. link 4 Beckmann CR, Trueblood JE, King ME, Tulsky AA. Juvenile adenofibromas. A case report. The Journal of reproductive medicine 1990. link 5 Subramony C. Bilateral breast tumors resembling syringocystadenoma papilliferum. American journal of clinical pathology 1987. link 6 Chan YF, Yeung HY, Ma L. Myxoma of the breast: report of a case and ultrastructural study. Pathology 1986. link 7 Tesluk H, Amott T, Goodnight JE. Apocrine adenoma of the breast. Archives of pathology & laboratory medicine 1986. link 8 Berean K, Tron VA, Churg A, Clement PB. Mammary fibroadenoma with multinucleated stromal giant cells. The American journal of surgical pathology 1986. link 9 Willén R, Willén H, Balldin G, Albrechtsson U. Granular cell tumour of the mammary gland simulating malignancy. A report on two cases with light microscopy, transmission electron microscopy and immunohistochemical investigation. Virchows Archiv. A, Pathological anatomy and histopathology 1984. link 10 Dharkar DD, Kraft JR. Benign chondrolipomatous tumour of the breast. Postgraduate medical journal 1981. link 11 Letterman G, Schurter M. Adenomammectomy. The Surgical clinics of North America 1977. link41341-1)

Malignant neoplasm of breast